Jubilant Ingrevia Ltd Share Price

JUBILIANT INGREVIA ENTERS INTO ELECTRONICS MANUFACTURING SECTOR

Specialty chemical player

will be acquiring a 40% stake in Zettaone Technologies for an amount of Rs 189.2 crore. Zettaone Technologies is an electronics design and manufacturing platform with integrated capabilities in electronics & semicon industry. This acquisition will allow the company to capitalise on it's proven manufacturing and customer-centric capabilities in CDMO space, while further strengthening it's engagement with customers across the electronics and semiconductor value chain. After the completion of the proposed acquisition, Zettaone Technologies will become an associate company of Jubilant Ingrevia.

See More

JUBILANT INGREVIA SHARES IN FOCUS AFTER ACQUIRING 40% STAKE IN ZETTAONE TECHNOLOGIES

Jubilant Ingrevia shares are likely to remain in focus after the company’s board approved a binding term sheet to acquire a 40% strategic stake in Zettaone Technologies India for approximately ₹189.2 crore. After completion, Zettaone will become an associate company of Jubilant Ingrevia. The acquisition will be completed in two tranches, with the first expected by November 2026 and the second by September 2027. The acquisition comes after a strong June quarter for Jubilant Ingrevia. The company reported a 41% year-on-year rise in consolidated net profit, while revenue from operations increased 25.3%. EBITDA also grew 40% year-on-year, indicating strong operating performance during the quarter. In the previous trading session, Jubilant Ingrevia closed at ₹725.90, down ₹6.40. The stock’s 52-week high stands at ₹794.95, recorded on July 22, 2026, placing it around 8.69% below the peak. The company currently has a market capitalisation of approximately ₹11,562 crore.

See More

Jubilant Ingrevia to Acquire 40% Stake in Zettaone Technologies for ₹189 Crore

Jubilant Ingrevia has entered into a binding agreement to acquire a 40% strategic stake in Zettaone Technologies India for approximately ₹189.2 crore, with the transaction expected to make Zettaone an associate company of Jubilant Ingrevia. The investment is interesting because it appears to be a strategic technology-oriented investment rather than a conventional capacity acquisition, potentially giving Jubilant Ingrevia access to capabilities that can complement its specialty chemicals and life-sciences businesses. The 40% structure also means Jubilant Ingrevia will have a significant strategic interest without taking full control of the company, which could limit the integration burden and capital requirement compared with a complete acquisition. From a fundamental perspective, the key question is whether Zettaone's technology and capabilities can eventually be integrated into or create new opportunities for Jubilant Ingrevia's existing businesses. The ₹189.2 crore investment is meaningful but not transformational for a company of Jubilant Ingrevia's scale, so the immediate impact on consolidated earnings is likely to be limited. More importantly, investors should focus on what specific capabilities Jubilant Ingrevia gains through this investment, how quickly they can be commercialised and what return the company ultimately earns on the ₹189 crore capital deployed. Since Zettaone will remain an associate rather than a wholly owned subsidiary, the financial contribution will also be different from that of a full acquisition. Overall, I would view this as a potentially positive long-term strategic development, but the investment thesis will depend heavily on the commercial benefits generated from the partnership rather than the transaction itself.

See More

JUBILANT INGREVIA SHARES IN FOCUS AFTER ACQUIRING 40% STAKE IN ZETTAONE TECHNOLOGIES

Jubilant Ingrevia’s share price is likely to remain in focus today after the company’s board approved entering into a binding term sheet to acquire a 40% strategic equity stake in Zettaone Technologies India for approximately ₹189.2 crore. Following the completion of the transaction, Zettaone will become an associate company of Jubilant Ingrevia. The acquisition will be completed in two tranches, with the first tranche expected to close by November 2026 and the second by September 2027. The development comes after a strong June quarter for the company. Jubilant Ingrevia reported a 41% year-on-year increase in consolidated net profit, while revenue from operations rose 25.3%. EBITDA increased 40% year-on-year. In the previous trading session, the stock closed at ₹725.90, down ₹6.40. The stock has traded between a 52-week high of ₹794.95, recorded on July 22, 2026. At its previous close, the stock was 8.69% below its 52-week high. Jubilant Ingrevia currently has a market capitalisation of approximately ₹11,562.22 crore.

See More

Jubilant Ingrevia Board Approves Zettaone Stake Acquisition

**Jubilant Ingrevia Board Approves Zettaone Stake Acquisition** Jubilant Ingrevia Limited (JUBLINGREA) announced that its Board of Directors has approved a **binding term sheet to acquire a 40% stake in Zettaone Technologies** for **₹189.2 crore**. The proposed transaction will give Jubilant Ingrevia a 40% stake in Zettaone Technologies, subject to the terms and conditions of the binding term sheet and completion of the transaction. Jubilant Ingrevia is a specialty chemicals and CDMO solutions provider serving pharmaceutical, nutrition, agrochemical, consumer, semiconductor and industrial customers. **Disclaimer:** This post is for informational purposes only and should not be construed as investment advice

See More